Journal of Clinical Oncology
Articles in this Issue
Comparative transcriptomic analysis of early- and late-onset colorectal cancer across TCGA, GEO, and CPTAC.
234 Background: Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related...
The efficacy of avapritinib for unresectable or metastatic gastrointestinal stromal tumors with and without PDGFRA D842V mutations: A meta-analysis.
834 Background: The FDA approved avapritinib for the treatment of unresectable or metastatic (UM) gastrointestinal stromal...
Primary analysis results of a phase II trial of laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer involving the greater curvature: JCOG1809.
363 Background: Advanced proximal gastric cancer (APGC) involving the greater curvature sometimes metastasized to the sple...
Optimizing the sequencing and timing of transarterial chemoembolization and systemic therapy in advanced hepatocellular carcinoma.
539 Background: Transarterial chemoembolization (TACE) and systemic therapy are widely used treatments for advanced hepato...
MTAP-deficient pancreatic adenocarcinoma: Clinical and molecular features.
742 Background: KRAS, TP53, CDKN2, and SMAD4 mutations are implicated in PDAC development and progression. Methylthioadeno...
IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
478 Background: Hepatocellular carcinoma (HCC) is among the most common and deadliest cancers worldwide. Locoregional trea...
TAS-102 plus bevacizumab in refractory metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials with validation from prospective single-arm studies.
174 Background: TAS-102 (trifluridine–tipiracil) provides modest benefit in refractory metastatic colorectal cancer (mCRC)...
Factors affecting overall survival in early-onset gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A multicenter database study using TriNetX.
626 Background: The incidence of early-onset gastroenteropancreatic neuroendocrine tumors (EO GEP-NETs), defined as diagno...
Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial.
282 Background: The NEOSUMMIT-01 trial evaluated the efficacy of adding the PD-1 antibody toripalimab to perioperative che...
Interim analysis of immunomodulatory low-dose radiotherapy plus chemoimmunotherapy as conversion therapy for locally advanced potentially/borderline resectable esophageal squamous cell carcinoma (ROICE trial): A phase II single-arm study.
412 Background: The optimal treatment strategy for locally advanced potential/borderline resectable esophageal squamous ce...
Bridging gaps in colorectal cancer care: Real-world impact of a national clinical navigation program.
36 Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, with an estimated...
Real-world outcomes comparing the use of GLP-1 agonists in patients with colon cancer and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.
83 Background: Colon cancer is among the leading causes of cancer-related morbidity and mortality globally, with an increa...
Longitudinal dietitian follow-up after pancreatectomy and post-operative outcomes.
695 Background: Adequate nutrition is essential to post-operative recovery in reducing complications and hospital length o...
Efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX or FOLFIRI plus drug-eluting bead transarterial chemoembolization in unresectable colorectal liver metastases.
53 Background: Liver metastases are the main cause of death in colorectal cancer (CRC), yet only ~20% of patients qualify...
Pattern of progression in advanced hepatocellular carcinoma treated with immunotherapy.
510 Background: Radiological progression patterns have long been recognized as prognostic indicators in hepatocellular car...
Induction DCF plus nivolumab versus induction DCF for unresectable locally advanced esophageal squamous cell carcinoma.
316 Background: Definitive chemoradiotherapy (dCRT) is the standard for unresectable locally advanced esophageal squamous...
Reevaluating complete response: Assessing whether imaging alone is sufficient to predict survival after transarterial radioembolization in hepatocellular carcinoma.
495 Background: Transarterial Radioembolization (TARE) is an emerging modality for hepatocellular carcinoma (HCC). Underst...
Neoadjuvant immune checkpoint inhibitors (ICIs) for localized dMMR/MSI-h gastroesophageal cancers (GEC): A systematic review with meta-analysis.
373 Background: Recent studies have demonstrated encouraging outcomes with neoadjuvant ICIs in pts with localized deficien...
Impact of claudin-1 (CLDN1) expression on molecular correlates and clinical outcomes in patients with advanced biliary tract cancers (BTCs).
602 Background: The tight junction protein CLDN1 is a potential therapeutic target in many cancers where its dysregulation...
The cost of care: How insurance status and socioeconomic factors affect colorectal cancer outcomes in Appalachia.
106 Background: Colorectal cancer (CRC) is a leading cause of cancer mortality, with outcomes influenced by early detectio...
Neo-adjuvant radiotherapy prior to endoscopic submucosal dissection for superficial esophageal squamous cell neoplasia: Impact and outcomes.
401 Background: The occurrence of esophageal stenosis becomes unavoidable with endoscopic submucosal dissection (ESD) cond...
Characterization of DPYD variants across ancestries in a large real-world cohort of cancer patients.
814 Background: Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, m...
Survival outcomes following stereotactic MR guided adaptive radiation therapy (SMART) in medically inoperable pancreatic cancer.
786 Background: There is ongoing interest in randomized studies utilizing stereotactic MR guided adaptive radiation therap...
Epidemiology and sociodemographic trends of hepatocellular carcinoma in Nevada: A decade-long statewide analysis.
483 Background: Hepatocellular carcinoma (HCC) incidence is rising nationwide, but state specific trends for Nevada remain...
Isocitrate dehydrogenase 1 mutations in biliary tract cancer patients in Spanish RETUD registry.
500 Background: Isocitrate dehydrogenase 1 mutations (IDH1mut) define a distinct molecular subtype of biliary tract cancer...